Opportunity

Federal Register #2026-23366

FDA determination on potential generic applications for M.V.I. ADULT injection

Buyer

Food and Drug Administration

Posted

November 17, 2026

Identifier

2026-23366

The FDA issued a regulatory determination concerning potential generic applications for M.V.I. ADULT multiple vitamins for injection. - Government buyer: None; this is a regulatory notice from the U.S. Department of Health and Human Services, Food and Drug Administration (FDA), not a procurement. - Product: M.V.I. ADULT, a multiple-vitamin injection. The listed formulation per vial contains ascorbic acid 200 mg, biotin 0.06 mg, cyanocobalamin 0.005 mg, dexpanthenol 15 mg, ergocalciferol 0.005 mg, folic acid 0.6 mg, niacinamide 40 mg, pyridoxine hydrochloride 6 mg, riboflavin 5′-phosphate sodium 3.6 mg, thiamine hydrochloride 6 mg, vitamin A 1 mg, vitamin E 10 mg, and vitamin K 0.15 mg. - OEM/companies mentioned: Hospira, Inc. held the original NDA; Apotex, Inc. submitted the citizen petition that prompted the review. - FDA determined that M.V.I. ADULT was not withdrawn from sale for reasons of safety or effectiveness. This allows FDA to consider abbreviated new drug applications (ANDAs) for the formulation, subject to other applicable requirements. - No products or services are being solicited for purchase; no procurement quantities, part numbers, or performance period are specified.

Description

The FDA determined that M.V.I. ADULT (multiple vitamins for injection) was not withdrawn from sale for reasons of safety or effectiveness. The determination allows FDA to approve abbreviated new drug applications for the listed formulation if all other legal and regulatory requirements are met. The formulation includes 13 listed vitamins and related ingredients at specified amounts per vial. The notice concerns FDA’s review following a citizen petition.

View original listing